Branding Pharmaceutical Drugs in China

June 04, 2013

Did you know according to the Chinese Association for Pharmaceutical Equipment group that the Chinese pharmaceutical industry has been growing at an average annual rate of 16.72% over the last few decades? And that growth isn’t going to slow down anytime soon. China stands at the cusp of a modern society with an increasingly affluent […]

Continue Reading

Why INN’s are so Important to a Drug’s Life

July 01, 2011

Every pharmaceutical asset begins with a nonproprietary, generic name, or an International Nonproprietary Name (INN). This name could potentially be the first strategic decision you make for the commercial life of your brand. But what exactly is an INN name and why do they exist? Since the inception of the INN naming system in 1950 […]

Continue Reading

Tobacco Gets Graphic

June 22, 2011

If you plan to purchase cigarette packs after September 2012 you may be surprised, or even disturbed by what you see. The Food and Drug Administration is requiring graphic warning labels with images ranging from a man exhaling smoke through a tracheotomy hole in his neck to a diseased lung to be placed prominently on […]

Continue Reading

FDA Approval: Edarbi

February 28, 2011

FDA approves Edarbi to treat high blood pressure (source: FDA Press Announcement) On Friday, February 25, 2011, The U.S. Food and Drug Administration approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults. Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other […]

Continue Reading

FDA Approval: Viibryd

January 24, 2011

Clinical Data, Inc. (NASDAQ: CLDA), today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD). Viibryd is a new molecular entity and the first and only selective serotonin reuptake inhibitor and 5HT1A […]

Continue Reading

FDA Approval: Brilique

December 06, 2010

LONDON, Dec 6 (Reuters) – AstraZeneca’s new heart medicine Brilique — or Brilinta — won final clearance from EU regulators on Monday, putting it on track to compete with Plavix, the world’s second biggest-selling drug, next year. AstraZeneca is relying on revenues from the new product to offset expiring patents on some of its best-selling […]

Continue Reading

FDA Approval: Halaven

November 16, 2010

FDA Approves Eisai Inc. (ESALF.PK)’s Halaven For Late-Stage Breast Cancer 11/15/2010 SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. Breast cancer is the second leading […]

Continue Reading

FDA Approval: Ofirmev

November 10, 2010

PRNewswire via COMTEX News Network/ — Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced last week that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV(TM) (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to […]

Continue Reading

FDA Pharmaceutical Approval: Kapvay

October 04, 2010

FLORHAM PARK, N.J., Oct. 4 /PRNewswire/ — Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of the non-stimulant medication KAPVAY™ (clonidine hydrochloride) extended-release tablets, an extended-release oral formulation for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents ages 6-17 […]

Continue Reading

FDA Pharmaceutical Approval: Suboxone

August 31, 2010

According to ClinicaSpace, MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, today announced that its partner, Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc (LSE: RB), has received approval from the U.S. Food and Drug Administration (FDA) to market Suboxone® (buprenorphine HCl/naloxone […]

Continue Reading